Advertise here Publish your press releases here Sponsor BioPortfolio
Follow us on Twitter Sign up for daily news and research emails Contributors wanted

Search Results for "BIAL Pharmaceuticals"

15:38 EDT 23rd April 2014 | BioPortfolio

Original Source: Bial and Eisai

Founded in 1924, Bial is an international pharmaceutical group with products available in over 30 countries throughout four continents. BIAL is the largest Portuguese pharmaceutical company and is based in S. Mamede do Coronado, Portugal.

Matching Channels


Matching News

Sunovion Pharmaceuticals Inc. Announces FDA Approval of Aptiom ® (eslicarbazepine acetate) as Once - Daily Adjunctive Treatment of Partial - Onset Seizures

Marlborough, MA- Sunovion Pharmaceuticals Inc.(Sunovion) today announced that the U.S. Food and Drug Administration (FDA) approved Aptiom® (eslicarbazepine acetate),an antiepileptic drug (AED),for us...

Parkinson's Disease Global Clinical Trials Review, H2, 2013

Recently added to the BioPortfolio report store, Parkinson's Disease Global Clinical Trials Review, H2, 2013 is a new report from GlobalData published on 2013-10-30. This 151-page report is available...

Grass Pollen Allergy - Pipeline Review, H2 2013

Recently added to the BioPortfolio report store, Grass Pollen Allergy - Pipeline Review, H2 2013 is a new report from Global Markets Direct published on 2013-11-29. This 66-page report is available i...

Sunovion Pharmaceuticals Inc. to Present New Data on Aptiom® (eslicarbazepine acetate) at The American Epilepsy Society’s 67th Annual Meeting

Sunovion Pharmaceuticals Inc. (Sunovion) will present new research posters on Aptiom® (eslicarbazepine acetate) and data on antiepileptic drug (AED) use in the U.S. managed care...

Sunovion Pharmaceuticals Inc. Presents Phase 3 Pooled Analysis of Once-Daily Aptiom® (eslicarbazepine acetate) as Adjunctive Treatment for Partial-Onset Seizures

Sunovion Pharmaceuticals Inc. today announced results from a pooled analysis of three Phase 3, randomized, placebo-controlled trials (Studies 301, 302 and 304) evaluating the safe...

Sunovion Pharmaceuticals Inc. Presents Positive Results From Two Phase 3 Studies of Once-Daily Aptiom® (eslicarbazepine acetate) as Monotherapy Treatment for Partial-Onset Seizures

Patients with partial-onset seizures poorly-controlled on 1-2 AEDs who converted to APTIOM monotherapy had a further 30.9%-47.5% reduction in seizure frequency...

Once-Daily Aptiom® (eslicarbazepine acetate) for the Adjunctive Treatment of Partial-Onset Seizures Now Available in U.S. Pharmacies

Sunovion Pharmaceuticals Inc. (Sunovion) announced that Aptiom® (eslicarbazepine acetate), a once-daily antiepileptic drug (AED) indicated for use as adjunctive treatment of part...

The Epilepsy Market Will Grow 2 Percent Annually Through 2022 with Expanding Uptake of Third-Generation Brands

BURLINGTON, Mass., Dec. 16, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the market for epi...

Matching PubMed Articles


Search Whole site using Google

Search BioPortfolio:
Advertisement Advertisement